Dudediligence.

Recursion Pharmaceuticals, Inc

RXRXNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$26.1MSep ’24$4.5MDec ’24$14.7MMar ’25$19.2MJun ’25$5.2MSep ’25$35.5MDec ’25$6.5MMar ’26$7.7MJun ’26
Net income, by quarter
−$95.8MSep ’24−$178.9MDec ’24−$202.5MMar ’25−$171.9MJun ’25−$162.3MSep ’25−$108.1MDec ’25−$117.5MMar ’26−$131.0MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$10.2M$39.8M$44.6M$58.8M$74.7M
Gross profit$10.2M−$8.4M$2.0M$13.6M$3.7M
Operating income−$182.8M−$245.7M−$350.1M−$479.0M−$648.1M
Net income−$186.5M−$239.5M−$328.1M−$463.7M−$644.8M
Operating cash flow−$158.6M−$83.5M−$287.8M−$359.2M−$371.8M
Free cash flow−$198.4M−$120.6M−$299.7M−$372.9M−$378.3M
Cash$285.1M$549.9M$391.6M$594.4M$743.3M
Debtnone on filenone on file$1.1M$27.4M$18.7M
Shares outstanding170.3M191.0M234.3M396.8M528.2M